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ABSTRACT 
Background: Many developed countries are facing a major challenge to improve identification of 
individuals acutely and chronically infected with hepatitis C virus (HCV) infection. We explored the 
views and experiences of people who inject drugs (PWID) in relation to HCV testing, and diagnosis 
through a review and synthesis of qualitative research. 
Methods: Based on the thematic synthesis of qualitative research. Searches were conducted in 14 
databases and supplemented by reference checking, hand searching of selected journals, and searches 
of relevant websites. Studies of any qualitative design that examined the views and experiences of, 
and attitudes towards, HCV testing and diagnosis among PWID or practitioners involved in their care 
were included. Key themes and sub-themes were systematically coded according to the meaning and 
content of the findings of each study which proceeded to the preparation of a narrative account of the 
synthesis. 
Results: 28 qualitative studies were identified. We identified a number of overarching descriptive 
themes in the literature, finding overall that PWID hold complex and differing views and experiences 
of testing and diagnosis. Three major themes emerged: missed opportunities for the provision of 
information and knowledge; shifting priorities between HCV testing and other needs; and testing as 
unexpected and routine. Evidence of missed opportunities for the provision of knowledge and 
information about HCV were clear, contributing to delays in seeking testing and providing a context 
to poor experiences of diagnosis. Influenced by the nature of their personal circumstances, perceptions 
of the risk associated with HCV and the prioritisation of other needs acted both to encourage and 
discourage the uptake of HCV testing. Undergoing HCV testing as part of routine health assessment, 
and an unawareness of being testing was common. An unexpected positive diagnosis exacerbated 
anxiety and confusion. 
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Conclusions: This review has identified that there are modifiable factors that affect the uptake of HCV 
testing and experiences of HCV diagnosis among PWID. Intervention development should focus on 
addressing these factors. There is a need for further research that engages PWID from a diverse range 
of populations to identify interventions, strategies and approaches that they consider valuable. 
 
INTRODUCTION 
Worldwide, around 150 million people are chronically infected with the hepatitis C virus (HCV) and 
injecting drug use is an important risk factor for acquiring the infection in high-income countries 
(World Health Organization, 2012a). HCV infection is highly prevalent among people who inject 
drugs (PWID), varying from around 60–80% of PWID infected across national samples in Western 
Europe, the USA and Canada (Nelson et al., 2011). Early diagnosis of HCV provides the best 
opportunity for effective medical support and the prevention of further transmission (Corey, Mendez-
Navarro, Gorospe, Zheng, & Chung, 2010). However, despite the high burden of disease associated 
with HCV, it is still a neglected disease in many countries and many individuals remain unaware of 
their HCV positive status (Volk et al., 2009; Mühlberger et al., 2009). The World Health Organization 
has recognised the need to integrate proven public health strategies for preventing viral hepatitis 
across health systems (World Health Organization, 2012b). However, while effective government-led 
programmes to improve screening have been implemented in some European countries (for example 
France; Hatzakis et al., 2011), in others, including Australia (Hopwood & Treloar, 2004), the UK 
(Morris, 2011) and USA (Volk et al., 2009), evidence suggests continued variation in the availability 
and uptake of HCV testing, treatment, care and support services. Many high-income countries are 
therefore facing a major challenge to improve the identification of individuals with HCV infection. In 
order to inform policy and practice responses and to address questions about appropriateness and 
acceptability of interventions aimed at increasing HCV testing uptake, we carried out a systematic 
review of qualitative research. The purpose of the review was to provide a narrative perspective on 
how PWID view HCV testing, their experiences of the communication of test results and what they 
perceive as the barriers and facilitators to participation in these strategies. 
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METHODS 
This study was conducted as part of a series of extensive systematic reviews to inform evidence-based 
policy recommendations on ways of offering hepatitis B and C testing in England by the UK National 
Institute for Health and Clinical Excellence (NICE). We used established methods for the thematic 
synthesis of qualitative research (Thomas & Harden, 2008) to explore the views and experiences of 
PWID, and health professionals involved in their care, in relation to HCV testing and diagnosis. This 
method was chosen as it enabled us to examine research addressing questions relating to need, 
appropriateness and acceptability of interventions aimed at increasing HCV testing uptake and 
subsequently develop analytical themes that could be used to inform intervention development. The 
following four research questions were formulated in relation to the views and experiences of PWID, 
and health professionals involved in their care: 
1: What are their knowledge, beliefs and practices to HCV?  
2: What are their experiences of barriers and facilitators to HCV testing and diagnosis?  
3: What are their views, experiences and attitudes of HCV testing, diagnosis, and communication of 
test results? 
4: What are their views and perspectives on opportunities for changing behaviour in relation to HCV 
testing and diagnosis 
 
Literature searching 
We utilised a combination of strategies to locate evidence for the review, including searching 
electronic sources, reference checking of included studies and key review articles, hand searching of 
selected journals, and searches of relevant websites. A detailed search strategy was developed for 14 
databases using a combination of free text and thesaurus terms for HCV combined with free text and 
thesaurus terms for qualitative methods, and population or social factors (see the example search 
strategy in the e-only Supplementary files). Searches were conducted in March and April 2011 and 
limited to studies published since 1990. Following the initial screening of titles and abstracts, 
potentially relevant references were examined to identify the five journals with the highest yield of 
references (Australian Health Review, Gastroenterology Nursing, International Journal of Drug Policy, 
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Journal of Community Health, and the Journal of Viral Hepatitis). All journal issues (and supplements) 
published between 2008 and 2011 were hand searched comprising a total of 113 issues. 
 
Study selection 
Two reviewers from a team of four (LJ, EMC, GB and LP) independently screened 6,255 titles and 
abstracts retrieved from the database searches according to the inclusion and exclusion criteria 
described. Based on title and abstract screening, 285 potentially relevant articles were identified and 
screened by two reviewers independently from the same team of four. Hand searching identified a 
further 36 articles but after removal of duplicates only one article was potentially relevant. No further 
relevant articles were identified by checking reference lists or review articles. We included studies of 
any qualitative design, including the qualitative elements of mixed methods research. We excluded 
studies that focused solely on general population groups or other groups at risk of HCV infection 
where it was not possible to attribute the findings to current and/or former PWIDs, studies that 
included only HCV/HIV co-infected individuals and studies that used structured questionnaires as the 
sole method of data collection or that reported only quantitative data. A summary of study 
identification is provided in a flowchart within the e-only Supplementary files. 
 
Thematic synthesis 
Verbatim findings of the included studies were extracted with brief information about the study 
methodology. Key themes and sub-themes were coded line by line according to the meaning and 
content of the findings of each study using NVivo 9 software. Coding of each study was undertaken 
by one reviewer (AA) and a second reviewer (LJ) checked the consistency of the key themes and sub-
themes that emerged by reference to a random subset of the studies identified for inclusion. Two 
reviewers (AA and LJ) independently assessed the quality of the individual studies in accordance with 
Methods for the development of NICE public health guidance (National Institute for Health and 
Clinical Excellence, 2009). By examining the findings of each included study, descriptive themes 
were independently coded by one reviewer. Once all of the included studies had been examined and 
coded, the resulting themes and sub-themes were discussed as a team (AA, LP and LJ). The 
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qualitative synthesis then proceeded to the development of descriptive themes and analytical themes 
(Thomas & Harden, 2008), which were interpreted by the wider review team (AA, LP and LJ). In 
addition, two reviewers (AA, LJ), first independently and then in discussion, reconsidered the findings 
of the qualitative synthesis to draw out clear implications for intervention development in the context 
of the four overarching research questions. A narrative account of the synthesis was prepared and 
quotations taken directly from the included studies were used to support the analytical and descriptive 
themes discussed. 
 
RESULTS 
Twenty-eight studies were identified for inclusion (table 1). The majority of studies included people 
who had acquired, or were at risk of acquiring, infection though injecting drug use; one of which 
focused on people in, or recently released from, prison (Khaw, Stobbart, & Murtagh, 2007). Two 
studies included the views of health professionals involved in the care of PWIDs; one as the sole 
study participants (Perry & Chew-Graham, 2003) and one, in addition to the views and experiences of 
PWID (Munoz-Plaza, Strauss, Astone, Jarlms, & Hagan, 2004). Most studies specifically examined 
views and experiences in relation to HCV infection only, though two studies (Gyarmathy, Neaigus, 
Ujhelyi, Szabo, & Racz, 2006; Lally, Montstream-Quas, Tanaka, Tedeschi, & Morrow, 2008) 
explored viral hepatitis infection more broadly alongside sexually transmitted infections such as HIV 
(table 1). 
**INSERT TABLE 1 ABOUT HERE** 
 
The included studies covered testing and the impact of diagnosis, including barriers and facilitators to 
testing, experiences of testing, reactions to diagnosis, and the impact of diagnosis on behaviour, and 
stigma as a barrier to testing uptake and disclosure. Our review identified a number of overarching 
descriptive themes in the literature, finding overall that PWID hold complex and differing views and 
experiences of testing and diagnosis. Three major themes emerged from the analysis of the descriptive 
themes: missed opportunities for the provision of information and knowledge; shifting priorities 
between HCV testing and other needs; and testing as unexpected and routine.  
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Missed opportunities for the provision of knowledge and information 
That opportunities for the provision of knowledge and information about HCV had been missed was a 
clear theme in a number of studies included in the synthesis. Negative views and experiences of 
testing and diagnosis were contextualised in many cases by the limited provision of information by 
health professionals, and an individual awareness of incomplete or partial knowledge of HCV by 
PWID. A lack of knowledge of HCV symptoms and transmission were common among PWID (Davis 
& Rhodes, 2004; Rhodes, Davis, & Judd, 2004; Gyarmarthy et al., 2006; Lally et al., 2008; Ellard, 
2007), particularly among those who had not previously been tested (Davis & Rhodes, 2004). Such 
gaps contributed to delays in seeking testing (Strauss et al., 2008; Swan et al., 2010; Lally et al., 2008; 
Southgate, Weatherall, Day, & Dolan, 2005) and individual barriers to testing uptake among PWID, 
such as fear, were often related to incomplete knowledge about HCV. 
 
Once a week we'd do groups on women, health issues and things like that and this one week was 
about hep C. And he (a doctor) said, ‘Hands up the people that have got it’ and everyone put their 
hand up except for me and I said, ‘Well, I've not been tested... but I can't remember being yellow 
or anything like that’. (Southgate et al., 2005, pg. 4.) 
 
People are frightened to get the test ye na [you know], thinking that it could be a killer not 
knowing what, not knowing what it actually is, what it actually does to you, I mean? (Khaw et al., 
2007, pg. 3.) 
 
Experiences of being informed on the outcome of testing were generally poor. Many PWID remained 
unclear about the meaning of a diagnosis and experienced limited and inadequate information 
provision by health professionals, leading to substantial gaps in knowledge (Copeland, 2004; Cullen, 
Kelly, Stanley, Langton, & Bury, 2005; Faye & Irurita, 2003; Khaw et al., 2007; Lally et al., 2008; 
Rhodes et al., 2004; Southgate et al., 2005; Strauss et al., 2008; Sutton & Treloar, 2007; Swan et al., 
2010; Temple-Smith, Gifford, & Stoové, 2004; Tompkins et al., 2005). A policy of not informing 
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PWID of the outcomes of testing (“a no news is good news approach”), as described in two drugs 
services (Munoz-Plaza et al., 2005), also produced anxiety.  
 
[On receiving their diagnosis while in prison] I got it (the diagnosis) off a bit of paper… it was 
slipped under the door in my cell. (Temple-Smith et al., 2004, pg. 51) 
 
Not bothered because I didn’t know what it was (Copeland, 2004, pg. 140) 
 
Responses to a positive diagnosis depended on individual circumstances (Craine, Walker, Carnwath 
& Klee, 2004) but feelings of unconcern or denial among some PWID were commonly underpinned 
by a lack of knowledge. In many studies PWID had experienced difficulties in obtaining reliable 
information following testing, regardless of whether they received a positive or negative diagnosis 
(Astone, Strauss, Munoz-Plaza, Hagan, & Des Jarlais, 2005; Carrier, LaPlante, & Bruneau, 2005; 
Copeland, 2004; Lally et al., 2008; Rhodes et al., 2004).  
 
Shifting priorities between HCV testing and other health needs 
Studies showed that influenced by the nature of their personal circumstances, their drug use and the 
extent to which they were engaged with ‘mainstream’ society, PWID expressed a motivation to, or 
actively, sought testing due to concerns both related and unrelated to their injecting behaviour and 
broader health needs. PWID perceived themselves as never being completely safe from, or in control 
of HCV transmission despite their intentions and actions to reduce risk (Carrier et al., 2005; Davis, 
Rhodes, & Martin, 2004; Davis & Rhodes, 2004; Harris, 2009b; Rhodes, Davis, & Judd, 2004; Roy, 
Nonn, Haley, & Cox, 2007; Sutton & Treloar, 2007; Swan et al., 2010; Wozniak, Prakash, Taylor, & 
Wild, 2007). However, there were exceptions, with studies noting that the extent to which PWID 
participated in the ‘normalised discourse’ was influenced by their situation, social context and 
personal relationships (Wozniak et al., 2007; Roy et al., 2007; Harris, 2009b). While PWID were 
motivated by concerns that they may have acquired HCV through injecting and the belief that HCV 
was an expected consequence of injecting drug use (Khaw et al., 2007; Roy et al., 2007; Swan et al., 
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2010; Temple-Smith et al., 2004; Wozniak et al., 2007) there was also evidence that PWID perceived 
themselves to be at low risk of infection related to a belief in the minimisation of infection risk within 
their injecting network (Gyarmarthy et al., 2006). In a UK study (Perry & Chew-Graham, 2003) of 
GP’s experiences of HCV testing, denial of possible infection among PWID was viewed as a barrier 
to the informed consent process and therefore testing. Lally and colleagues also noted that for some 
PWID a prioritization of obtaining drugs was perceived as interfering with their ability to attend to 
their health needs. 
 
[GP in a methadone clinic] Either they understand that they’re going to address their lifestyle, or 
they don’t understand and it will make no difference... (Perry & Chew-Graham, 2003, pg. 542) 
 
I care, but the last thing on my mind is going to get tested… (Lally et al., 2008, pg. 56) 
 
The only reason I did decide to get tested for Hep was because I was an IV drug abuser, and that 
was the only reason. I was never symptomatic.” (Wozniak et al., 2007, pg. 392) 
 
Reactions to a positive diagnosis, primarily among people who were injecting drugs at the time of 
diagnosis, included being unaware of or indifferent to the meaning of a positive diagnosis, and 
commonly denial (Astone et al., 2005; Copeland, 2004; Faye & Irurita, 2003; Swan et al., 2010; 
Temple-Smith et al., 2004). A diagnosis of HCV (Harris, 2009b; Roy et al., 2007) was not viewed as 
overly concerning as there was a perception of HCV as a health condition that developed over many 
years; as such HCV was viewed as inconsequential relative to other disruptions, for example, a drugs 
overdose. However, injecting behaviour was also a motivation for testing with PWID citing social or 
personal responsibility to others, such as those within their injecting networks (Craine et al., 2004; 
Khaw et al., 2007; Roy et al., 2007). For those with concerns about a positive diagnosis, anxiety over 
the impact of HCV on the chances of finding a long term partner, sexual relations, starting a family 
and the possibility of transmission predominated (Carrier et al., 2005; Harris, 2009b; Temple-Smith et 
al., 2004; Tompkins et al., 2005; Wright, Tompkins, & Jones, 2005). A positive diagnosis led some 
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PWID to re-evaluate their lives and make the first steps towards a life away from their drug use (Roy 
et al., 2007; Sutton & Treloar, 2007; Swan et al., 2010) or towards adopting a healthier lifestyle, such 
as eating more healthily and reducing alcohol and drug use (Cullen et al., 2005; Faye & Irurita, 2003; 
Khaw et al., 2007; Roy et al., 2007; Sutton & Treloar, 2007; Wozniak et al., 2007; Wright et al., 
2005). 
 
I was sick of it [...], I was sick, I found out I had hepatitis C, I had to stop using [drugs]. It didn’t 
make sense anymore. (Roy et al., 2007, pg. 402.) 
 
HCV was often understood relative to HIV; a product of joint testing procedures, a bias towards HIV 
services in practice, the relative trivialisation in comparison to HIV by others (including health 
professionals) and the social dominance of popular HIV discourse since the 1980’s (Davis & Rhodes, 
2004; Harris, 2009a; Khaw et al., 2007; Munoz-Plaza et al., 2010; Rhodes et al., 2004). Studies that 
described the trivialisation of a positive HCV diagnosis, relating both to those delivering (Rhodes et 
al., 2004) and those receiving the diagnosis (Roy et al., 2007; Copeland, 2004; Carrier et al., 2005; 
Cullen et al., 2005), noted that this trivialisation tended to be relative and in comparison to a HIV 
diagnosis.  
 
Testing as unexpected and routine  
Studies showed that undergoing routine testing was common among PWID, but when consent for 
testing was not explicitly sought, this exacerbated anxiety and confusion over a positive diagnosis. At 
a structural level, convenient and opportunistic testing were important facilitators for testing. 
Participants in many studies had experienced HCV testing opportunistically as part of routine health 
assessments (Craine et al., 2004; Lally et al., 2008; Munoz-Plaza et al., 2005; Rhodes et al., 2004; 
Swan et al., 2010; Tompkins, Wright, & Jones, 2005) and among those unlikely to deliberately seek 
testing, had been an important facilitator of testing uptake (Rhodes et al., 2004; Temple-Smith et al., 
2004). 
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[Registered Nurse at a drug treatment programme] From fasting blood sugar to lipids, Hep B, Hep 
C, Hep A, rubella... So, they're explained what everything is... And we don't do HIV unless it is 
requested, obviously... But the Hep C is just done... It's a done deal.” (Munoz-Plaza et al., 2005, pg. 
664) 
 
Concerns over informed consent related to routine testing were raised in a number of studies (Munoz-
Plaza et al., 2005; Rhodes et al., 2004; Tompkins et al., 2005). Studies showed that when testing was 
routine, PWID were often unaware that they had been tested and although this was perceived by some 
(among both PWID and providers) as non-problematic (Munoz-Plaza et al., 2005), studies showed 
that an expectation of testing was concerning for some and restricted patient choice. In addition, for 
those who participated in testing, an unexpected diagnosis exacerbated anxiety and confusion (Rhodes 
et al., 2004; Swan et al., 2010; Lally et al., 2008; Tompkins, Wright, & Jones, 2005). 
 
I think they have to [take your blood]. It’s not an option… it should be like if you want it or not, 
it’s an option, you know, but they did do it anyway… (Munoz-Plaza et al., 2005, pg. 665) 
 
Positive experiences of testing were rare, but studies conducted within drugs services identified that 
trust and rapport with health professionals and drug treatment staff, and support and encouragement 
were important motivators for testing (Munoz-Plaza et al., 2005; Strauss et al., 2008). When asked 
about convenient locations for testing, some PWID referred to drug treatment programme sites and 
methadone clinics (Munoz-Plaza et al., 2004; Strauss et al., 2008) whilst others expressed a 
preference for primary care settings (Temple-Smith et al., 2004). 
 
DISCUSSION 
This review sought to examine the views and experiences of PWID in relation to HCV testing and 
diagnosis through a review and synthesis of qualitative research. Our review of 28 qualitative studies 
showed that despite holding complex views and differing experiences, in relation to HCV testing and 
diagnosis, PWID experienced missed opportunities for the provision of knowledge and information, 
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had shifting priorities around HCV testing and their other health needs, and experienced testing as 
unexpected and routine.  
 
The evidence identified through this review suggests that there are modifiable factors that could be 
addressed through interventions that aim to encourage HCV testing uptake. As noted by Bruggmann 
(2012), increasing access to testing requires the breakdown of barriers at multiple levels; at a 
healthcare system level, provider level, and indirectly at an individual patient level. A recent 
systematic review of the effectiveness of interventions aimed at increasing HCV testing uptake (Jones, 
Bates, McCoy, Beynon, McVeigh & Bellis, 2013) identified eight controlled studies that examined a 
range of intervention approaches, including those designed to enhance case finding and testing uptake 
in primary care, offer alternative methods of testing, deliver services in non-specialist community 
settings and improve HCV management among health professionals. The effects of the interventions 
on testing uptake were variable and a comparison with the themes identified in this review suggest 
that factors identified in the qualitative research have yet to be fully addressed. Appropriate 
interventions are required to tackle knowledge and awareness of HCV, and how such knowledge is 
disseminated between health care providers and PWID. By targeting health professionals’ 
management of HCV, complex interventions that go some way to addressing this factor have shown 
promise (Helsper, van Essen, Bonten, & de Wit, 2010; Cullen, Stanley, & Langton, 2006). For 
example, a nurse-led intervention supporting the implementation of clinical guidelines in primary care 
improved HCV testing rates amongst PWID receiving methadone maintenance treatment (Cullen et 
al., 2006). HCV is a relative concern among PWID (Rhodes & Treloar, 2008; Harris & Rhodes, 2013). 
Acknowledgement of shifting priorities among PWID requires consideration in intervention 
development and in relation to how consent for testing is understood and obtained. The importance 
and need to integrate peer support in pre- and post-test discussions should also be considered (Treloar, 
Newland, Harris, Deacon, & Maher, 2010). However, interventions studies are lacking that address 
these factors. To address testing as routine and unexpected, healthcare services are required that meet 
the specific and unique needs of people who use drugs (Bruce, 2012). Structural barriers need to be 
tackled and opportunities for PWID to access testing and other HCV services enhanced through 
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multidisciplinary or shared care approaches (Grebely, de Vlaming, Duncan, Viljoen, & Conway, 
2008). In a UK study, HCV testing uptake was increased by offering dry blood spot testing within 
substance misuse services, drug clinics and prisons (Hickman et al., 2008). In addition, evidence from 
two recent case series (Jack, Willott, Manners, Varnam, & Thomson, 2009; Lindenberg et al., 2011) 
suggests that shared care approaches may be associated with good uptake of follow-up services for 
HCV, and treatment outcomes considered comparable to those seen in non-drug using populations. 
Reducing stigma and discrimination related to HCV and PWID is also essential in breaking down 
barriers to access (Grebely & Dore, 2011; Treloar, Rance, & Backmund, 2013). This review identifies 
that research is lacking on what PWID think could be done to increase uptake of testing and to 
improve experiences related to a HCV diagnosis. There is therefore a need for research that engages 
with a diverse range of injecting populations to identify interventions, strategies and approaches that 
they consider valuable. 
 
As with other syntheses of qualitative research there were limitations associated with this review. 
Overall, the usefulness of all of the included studies was considered to be adequate and the vast 
majority of studies reported rich, detailed and convincing findings and conclusions. However, this 
review was unable to fully consider the influence of context and setting. Studies were conducted with 
diverse samples across a range of settings with differences in healthcare systems, accessibility to 
testing and circulating background information about the need for testing. We also found that it was 
difficult to disaggregate the views and experiences of hidden populations affected by HCV, such as 
former users of injecting drugs, from the broader literature on current PWID. In some settings these 
populations may comprise a significant proportion of individuals with undiagnosed chronic HCV 
(Cullen et al., 2012). The applicability of the themes arising from this synthesis should therefore be 
considered and verified according to the setting and context of local PWID populations. There is also 
the possibility that relevant literature was missed during the searches conducted for this review. 
However, a comprehensive search protocol was prepared for the review that incorporated searching of 
a range of electronic sources, web-based searches and hand searching, and as a range of literature 
sources were searched, it is unlikely that key studies were missed. 
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This review provides evidence to show that there are modifiable factors that affect the uptake of HCV 
testing and experiences of diagnosis among PWID. While existing interventions go some way to 
addressing these factors, this review has shown that gaps exist and that future development of 
interventions should consider addressing the broader array of factors identified here. The review also 
identifies that there is a clear need for research that engages PWID from a diverse range of 
populations to identify interventions, strategies and approaches that they consider valuable. 
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Table 1. Description of included studies 
Study Country Study type  Population Recruitment source Major descriptive themes 
Astone et al., 
2005   
USA Interviews, 
focus groups 
49 male and female PWIDs 
with HCV (58% male) 
Methadone maintenance 
treatment programmes 
Experience of testing and reactions to diagnosis 
Carrier et al., 
2005   
Canada Interviews, 
observations  
36 male and female PWIDs 
(75% male) 
Drug services (needle 
exchange facility and drop-
in resource), street and 
public parks 
HCV as normal, ubiquitous and socially accepted; 
incomplete and uncertain knowledge of HCV; barriers and 
facilitators to testing; experience of testing and reactions to 
diagnosis; the impact of testing on behaviour; stigma as a 
barrier to disclosure. 
Copeland, 2004   UK Interviews 16 male and female current 
or former PWIDs with HCV 
(antibody positive) (56% 
male) 
A single medical practice HCV as normal, ubiquitous and socially accepted; 
incomplete and uncertain knowledge of HCV; relative 
understanding of HCV; barriers and facilitators to testing; 
experience of testing and reactions to diagnosis; impact of 
diagnosis on behaviour. 
Craine et al., 
2004   
UK Interviews 43 PWIDs (24 tested for 
HCV) (% male NR) 
Drug treatment services Barriers and facilitators to testing; experience of testing 
and reactions to diagnosis; impact of testing on behaviour; 
stigma as a barrier to disclosure. 
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Study Country Study type  Population Recruitment source Major descriptive themes 
Cullen et al., 
2005   
Ireland Survey  25 male and female current 
and past heroin users (22 
with HCV) (56% male) 
A single general practice Experience of testing and reactions to diagnosis; impact of 
diagnosis on behaviour. 
Davis & 
Rhodes 2004; 
Davis et al., 
2004  
UK Interviews 59 male and female current 
PWIDs (19 HCV positive) 
(68% male) 
Drug user networks, 
community-based drug 
services and snowballing 
HCV as normal, ubiquitous and socially accepted; 
incomplete and uncertain knowledge of HCV; relative 
understanding of HCV. 
Ellard, 2007   Australia Interviews  31 males and females (13 
PWIDs) (% male NR) 
Inner city dance/club scene Incomplete and uncertain knowledge of HCV; stigma as a 
barrier to disclosure. 
Faye & Irurita, 
2003   
Australia Interviews 24 people with HCV (13 
PWIDs) (% male NR) 
Substance use services Experience of testing and reactions to diagnosis; impact of 
diagnosis on behaviour. 
Gyarmathy et 
al., 2006   
Hungary Interviews, 
focus groups  
29 PWIDs aged ≤30 years 
(% male NR) 
Non treatment settings Incomplete and uncertain knowledge of HCV; barriers and 
facilitators to testing. 
Harris, 2009a; 
Harris, 2009b   
Australia Interviews 40 people with chronic HCV 
(34 former PWIDs) (45% 
male) 
HCV-related publications 
and websites 
HCV as normal, ubiquitous and socially accepted; relative 
understanding of HCV; experience of testing and reactions 
to diagnosis; stigma as a barrier to disclosure. 
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Study Country Study type  Population Recruitment source Major descriptive themes 
Khaw et al., 
2007   
UK Interviews 30 male and female 
prisoners who were former 
PWIDs (21 tested for HCV) 
(83% male) 
Three prisons Relative understanding of HCV; barriers and facilitators to 
testing; experience of testing and reactions to diagnosis; 
impact of diagnosis on behaviour. 
Lally et al., 
2008   
USA Interviews 20 female PWIDs  A single drug treatment 
centre 
Incomplete and uncertain knowledge of HCV; barriers and 
facilitators to testing; experience of testing and reactions to 
diagnosis. 
Munoz-Plaza et 
al., 2004   
USA Interviews, 
focus groups  
29 male and female drug 
treatment clients and 23 staff 
(41% male)  
Drug treatment service Barriers and facilitators to testing. 
Munoz-Plaza et 
al., 2005  
USA Interviews, 
focus groups  
51 male and female drug 
treatment clients (61% male) 
Drug treatment service Barriers and facilitators to testing; experience of testing 
and reactions to diagnosis. 
Munoz-Plaza et 
al.,  2010  
USA Interviews, 
focus groups  
215 male and female drug 
treatment clients; 165 staff 
members 
14 drug treatment 
programmes 
Relative understanding of HCV. 
Perry & Chew-
Graham, 2003   
UK Interviews 20 general practitioners Drug treatment services Experience of testing and reactions to diagnosis. 
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Study Country Study type  Population Recruitment source Major descriptive themes 
Rhodes et al., 
2004   
UK Interviews  59 male and female current 
PWIDs (68% male) 
Drug user networks, 
community-based drug 
services and snowballing 
HCV as normal, ubiquitous and socially accepted; 
incomplete and uncertain knowledge of HCV; relative 
understanding of HCV; barriers and facilitators to testing; 
experience of testing and reactions to diagnosis. 
Roy et al., 2007   Canada Interviews 39 street-involved young 
PWIDS (aged <30 years old) 
(59% male) 
On-going cohort study; 
methadone programmes 
and medical clinics 
HCV as normal, ubiquitous and socially accepted; relative 
understanding of HCV; barriers and facilitators to testing; 
experience of testing and reactions to diagnosis. 
Southgate et al., 
2005   
Australia Interviews, 
observations  
24 male and female current 
PWIDs (58% male) 
Open-air drug market and 
‘red light’ district 
Barriers and facilitators to testing; experience of testing 
and reactions to diagnosis. 
Strauss et al., 
2008   
USA Interviews 62 drug treatment clients (% 
male NR) 
11 drug treatment 
programmes 
Barriers and facilitators to testing; experience of testing 
and reactions to diagnosis; stigma as a barrier to disclosure. 
Sutton & 
Treloar, 2007   
Australia Interviews 36 people with HCVa (% 
male NR) 
Not reported HCV as normal, ubiquitous and socially accepted; 
experience of testing and reactions to diagnosis; impact of 
diagnosis on behaviour; stigma as a barrier to disclosure. 
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Study Country Study type  Population Recruitment source Major descriptive themes 
Swan et al., 
2010   
Ireland Interviews 36 male and female current 
and former PWIDs (33 with 
HCV) (78% male) 
Two addiction clinics, 
community drop-in centre, 
general practice, two 
hepatology clinics, and 
infectious diseases clinic 
HCV as normal, ubiquitous and socially accepted; barriers 
and facilitators to testing; experience of testing and 
reactions to diagnosis; impact of diagnosis on behaviour. 
Temple-Smith 
et al., 2004   
Australia Interviews 32 males and females with 
HCV (8 current and 22 
former PWIDs) (38% male) 
‘Key’ agencies (including 
needle-syringe exchanges, 
Liver Clinics, and 
Hepatitis C Council) 
HCV as normal, ubiquitous and socially accepted; barriers 
and facilitators to testing; experience of testing and 
reactions to diagnosis; impact of diagnosis on behaviour. 
Tompkins et al., 
2005   
UK Interviews 17 homeless PWIDs with 
HCV (88% male) 
Primary care centre Experience of testing and reactions to diagnosis; stigma as 
a barrier to disclosure. 
Wozniak et al., 
2007   
Canada Interviews 61 street-involved PWIDs 
(62% male) 
Needle exchanges and 
other harm reduction and 
health services; 
snowballing 
HCV as normal, ubiquitous and socially accepted; barriers 
and facilitators to testing; impact of diagnosis on 
behaviour. 
Wright et al., 
2005   
UK Interviews 17 homeless PWIDs with 
HCV (% male NR) 
 
A primary care health 
centre for homeless people 
Experience of testing and reactions to diagnosis; impact of 
diagnosis on behaviour; stigma as a barrier to disclosure. 
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Study Country Study type  Population Recruitment source Major descriptive themes 
a Number of PWIDs not report. HCV = hepatitis C virus. PWID = people who inject drugs. 
 
 
